TY - JOUR
T1 - Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy with Kaposi Sarcoma Risk among HIV-infected Persons in the United States and Canada
AU - the North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS
AU - Dubrow, Robert
AU - Qin, Li
AU - Lin, Haiqun
AU - Hernández-Ramírez, Raúl U.
AU - Neugebauer, Romain S.
AU - Leyden, Wendy
AU - Althoff, Keri N.
AU - Achenbach, Chad J.
AU - Hessol, Nancy A.
AU - Modur, Sharada P.
AU - D'Souza, Gypsyamber
AU - Bosch, Ronald J.
AU - Grover, Surbhi
AU - Horberg, Michael A.
AU - Kitahata, Mari M.
AU - Mayor, Angel M.
AU - Novak, Richard M.
AU - Rabkin, Charles S.
AU - Sterling, Timothy R.
AU - Goedert, James J.
AU - Justice, Amy C.
AU - Engels, Eric A.
AU - Moore, Richard D.
AU - Silverberg, Michael J.
N1 - Publisher Copyright:
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Background: Kaposi sarcoma (KS) remains common among HIV-infected persons. To better understand KS etiology and to help target prevention efforts, we comprehensively examined a variety of CD4+ T-cell count and HIV-1 RNA viral load (VL) measures, as well as antiretroviral therapy (ART) use, to determine independent predictors of KS risk. Setting: North American AIDS Cohort Collaboration on Research and Design. Methods: We followed HIV-infected persons during 1996-2009 from 18 cohorts. We used time-updated Cox regression to model relationships between KS risk and recent, lagged, trajectory, and cumulative CD4 count or VL measures, as well as ART use. We used Akaike's information criterion and global P values to derive a final model. Results: In separate models, the relationship between each measure and KS risk was highly significant (P < 0.0001). Our final mutually adjusted model included recent CD4 count [hazard ratio (HR) for <50 vs. ≥500 cells/L = 12.4; 95% confidence interval (CI): 6.5 to 23.8], recent VL (HR for ≥100,000 vs. ≤500 copies/mL = 3.8; 95% CI: 2.0 to 7.3), and cumulative (time-weighted mean) VL (HR for ≥100,000 vs. ≤500 copies/mL = 2.5; 95% CI: 1.0 to 5.9). Each P-trend was <0.0001. After adjusting for these measures, we did not detect an independent association between ART use and KS risk. Conclusions: Our results suggested a multifactorial etiology for KS, with early and late phases of development. The cumulative VL effect suggested that controlling HIV replication promptly after HIV diagnosis is important for KS prevention. We observed no evidence for direct anti-KS activity of ART, independent of CD4 count and VL.
AB - Background: Kaposi sarcoma (KS) remains common among HIV-infected persons. To better understand KS etiology and to help target prevention efforts, we comprehensively examined a variety of CD4+ T-cell count and HIV-1 RNA viral load (VL) measures, as well as antiretroviral therapy (ART) use, to determine independent predictors of KS risk. Setting: North American AIDS Cohort Collaboration on Research and Design. Methods: We followed HIV-infected persons during 1996-2009 from 18 cohorts. We used time-updated Cox regression to model relationships between KS risk and recent, lagged, trajectory, and cumulative CD4 count or VL measures, as well as ART use. We used Akaike's information criterion and global P values to derive a final model. Results: In separate models, the relationship between each measure and KS risk was highly significant (P < 0.0001). Our final mutually adjusted model included recent CD4 count [hazard ratio (HR) for <50 vs. ≥500 cells/L = 12.4; 95% confidence interval (CI): 6.5 to 23.8], recent VL (HR for ≥100,000 vs. ≤500 copies/mL = 3.8; 95% CI: 2.0 to 7.3), and cumulative (time-weighted mean) VL (HR for ≥100,000 vs. ≤500 copies/mL = 2.5; 95% CI: 1.0 to 5.9). Each P-trend was <0.0001. After adjusting for these measures, we did not detect an independent association between ART use and KS risk. Conclusions: Our results suggested a multifactorial etiology for KS, with early and late phases of development. The cumulative VL effect suggested that controlling HIV replication promptly after HIV diagnosis is important for KS prevention. We observed no evidence for direct anti-KS activity of ART, independent of CD4 count and VL.
KW - CD4 T-cell count
KW - HIV infection
KW - HIV-1 RNA viral load
KW - Kaposi sarcoma
KW - acquired immunodeficiency syndrome
KW - antiretroviral therapy
UR - http://www.scopus.com/inward/record.url?scp=85017210182&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017210182&partnerID=8YFLogxK
U2 - 10.1097/QAI.0000000000001394
DO - 10.1097/QAI.0000000000001394
M3 - Article
C2 - 28394855
AN - SCOPUS:85017210182
SN - 1525-4135
VL - 75
SP - 382
EP - 390
JO - Journal of Acquired Immune Deficiency Syndromes
JF - Journal of Acquired Immune Deficiency Syndromes
IS - 4
ER -